GLP-1 generics: what's real, what's hype, and what's missing
Quick answer
Teva's FDA-approved generic liraglutide 1.8mg is the first approved generic GLP-1 receptor agonist in the U.S., indicated for type 2 diabetes management in adults alongside diet and exercise. Liraglutide requires daily subcutaneous injection and has a well-established safety profile from over a decade of post-market data, though its weight-loss efficacy is lower than newer weekly GLP-1 and dual GIP/GLP-1 receptor agonists. The 1.8mg dose in this approval is not the dose used for weight management, which is 3mg under the Saxenda brand and remains under separate patent considerations.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @michaelalbertmd actually say?
The creator claims that "GLP1 generics are here" and that Teva (he said "Tevin") announced the first FDA-approved GLP-1 generic, specifically liraglutide 1.8mg, sold under the brand name Victoza. He describes it as a "short-acting daily injection" and says it is the molecule that semaglutide is "based off of." He frames this as a significant moment: "this is a very big deal because it's the first FDA-approved GLP1 generic."
The core claims are: Teva received FDA approval for a liraglutide generic, liraglutide is a first-generation GLP-1 agonist, it requires daily dosing, and semaglutide was derived from the liraglutide molecule. Let's break down which of those hold up.
Does the science back this up?
Mostly yes, with some important nuances. Teva did receive FDA approval for a generic liraglutide 1.8mg injection, making it the first approved generic GLP-1 receptor agonist in the United States. That part is accurate and genuinely significant from a regulatory standpoint.
Liraglutide's mechanism and history are well-documented. It was developed by Novo Nordisk and approved by the FDA in 2010 for type 2 diabetes under the brand Victoza, and later at 3mg as Saxenda for weight management. It is a daily subcutaneous injection, which the creator correctly identifies as "short-acting" relative to the weekly GLP-1 agents now dominating the market.
The structural relationship between liraglutide and semaglutide is also real. Both are GLP-1 receptor agonists derived from the native GLP-1 peptide sequence. Semaglutide was engineered from liraglutide with structural modifications, including a different fatty acid chain and amino acid substitutions, that extend its half-life to allow weekly dosing (Lau et al., 2015, Biochemistry). Calling semaglutide "based off" liraglutide is a reasonable simplification.
What did they get wrong (or right)?
The creator mispronounced both the company name ("Tevin" instead of Teva) and the drug name ("Lyric-Luteide" instead of liraglutide), which matters because misspellings in viral health content create search confusion for patients trying to verify information.
The framing that semaglutide is simply "based off the liraglutide molecule with a few changes" undersells the engineering involved. Semaglutide has a C18 fatty diacid attached via a linker to lysine at position 26, and an amino acid substitution at position 8, which together extend the half-life from roughly 13 hours for liraglutide to approximately 168 hours for semaglutide (Marso et al., 2016, NEJM). These are not trivial tweaks.
He is correct that this is a first-generation GLP-1 agonist and correct that it requires daily injection. He is also correct that this is a genuinely notable regulatory event. Credit where it is due: the core news hook is accurate.
One omission worth noting: generic liraglutide does not mean cheap liraglutide, at least not immediately. Generic pricing timelines vary, and the clinical efficacy of liraglutide for weight loss trails that of semaglutide and tirzepatide in head-to-head contexts.
What should you actually know?
This approval matters, but it is not a shortcut to the weight-loss results associated with Wegovy or Zepbound. Liraglutide at 3mg (Saxenda) produces average weight loss of around 5-8% of body weight, compared to 10-15% for semaglutide and up to 20-22% for tirzepatide (Wilding et al., 2021, NEJM; Jastreboff et al., 2022, NEJM). The 1.8mg dose approved for the generic is the diabetes dose, not the higher weight-management dose.
Patients should also understand that compounded versions of GLP-1 medications are not the same as FDA-approved generics. A generic must demonstrate bioequivalence to the reference product through a rigorous FDA review process. Compounded drugs do not go through that process. These are not interchangeable categories, and conflating them is a common source of confusion in GLP-1 social media content.
If you are currently on a compounded GLP-1 or considering options, talk to a licensed provider about what an approved generic actually means for your treatment options. Regulatory approval is step one. Accessibility and cost are separate questions that are still being worked out.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 generics: what's real, what's hype, and what's missing, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
GLP-1 generics: what's real, what's hype, and what's missing should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Teva's FDA-approved generic liraglutide 1.
FormBlends verdict
Teva's FDA-approved generic liraglutide 1.8mg is the first approved generic GLP-1 receptor agonist in the U.S., indicated for type 2 diabetes management in adults alongside diet and exercise. Liraglutide requires daily subcutaneous injection and has a well-established safety profile from over a decade of post-market data, though its weight-loss efficacy is lower than newer weekly GLP-1 and dual GIP/GLP-1 receptor agonists. The 1.8mg dose in this approval is not the dose used for weight management, which is 3mg under the Saxenda brand and remains under separate patent considerations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Teva's FDA-approved generic liraglutide 1.8mg is the first approved generic GLP-1 receptor agonist in the U.S., indicated for type 2 diabetes management in adults alongside diet and exercise. Liraglutide requires daily subcutaneous injection and has a well-established safety profile from over a decade of post-market data, though its weight-loss efficacy is lower than newer weekly GLP-1 and dual GIP/GLP-1 receptor agonists. The 1.8mg dose in this approval is not the dose used for weight management, which is 3mg under the Saxenda brand and remains under separate patent considerations.
- Teva's generic liraglutide 1.8mg is the first FDA-approved generic GLP-1 receptor agonist in the United States, a real regulatory first.
- The approved dose (1.8mg) is the type 2 diabetes dose. The weight-management dose for liraglutide is 3mg (Saxenda) and is not part of this generic approval.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Teva's generic liraglutide 1.8mg is the first FDA-approved generic GLP-1 receptor agonist in the United States, a real regulatory first.
- The approved dose (1.8mg) is the type 2 diabetes dose. The weight-management dose for liraglutide is 3mg (Saxenda) and is not part of this generic approval.
- Liraglutide produces roughly 5-8% body weight loss on average, compared to 10-15% for semaglutide and up to 22% for tirzepatide (Wilding et al., 2021, NEJM; Jastreboff et al., 2022, NEJM).
- An FDA-approved generic is not the same as a compounded GLP-1. Generics must demonstrate bioequivalence through FDA review. Compounded drugs do not.
- Semaglutide's extended weekly half-life came from deliberate structural modifications to the liraglutide backbone, not minor tweaks, including a C18 fatty diacid linker and amino acid substitution (Lau et al., 2015, Biochemistry).
- Generic approval does not guarantee immediate affordability. Insurance coverage, pharmacy contracts, and manufacturer pricing strategies all affect real-world patient cost.
- Liraglutide has over a decade of post-market safety data, which is a meaningful advantage over newer agents with shorter long-term track records.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Taking New Patients · TikTok creator
19.7K views on this video
#GLP1 Generics!
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Taking New Patients, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.